Table 1 Patient characteristics
All | Primary lung cancer | Metachronous lung cancer | p value | |
|---|---|---|---|---|
Number of Patients | 137 | 109 (79.6%) | 28 (20.4%) | |
Age (years)a | 77.8 (57.1–96.6) | 78.5 (57.6–96.6) | 76.6 (57.1–88.9) | 0.2 |
Follow-up (months)a | 53 (38.6–67.4) | 59.5 (40.2–78.7) | 39 (31.3–46.7) | 0.2 |
Gender | ||||
Male | 99 (72.3%) | 81 (74.3%) | 18 (64.3%) | 0.3 |
Female | 38 (27.7%) | 28 (25.7%) | 10 (35.7%) | |
Smoking (pack-years)a | 50 (0–180) | 50 (0–180) | 47.5 (0–140) | 0.8 |
ECOG | ||||
0 | 69 (50.4%) | 52 (47.7%) | 17 (60.7%) | 0.2 |
1–2 | 68 (49.6%) | 57 (52.3%) | 11 (39.3%) | |
Histology | ||||
Squamous | 38 (27.7%) | 26 (23.9%) | 12 (42.9%) | 0.13 |
Non squamous | 53 (38.7%) | 45 (41.3%) | 8 (28.6%) | |
Adenocarcinoma | 33 (30.3%) | 4 (14.3%) | ||
Undifferentiated | 11 (10.1%) | 4 (14.3%) | ||
Unknown | 46 (33.6%) | 38 (34.9%) | 8 (28.6%) | |
TNM stage | ||||
T1(N0M0) | 83 (60.6%) | 68 (62.4%) | 15 (53.6%) | 0.4 |
T1a | 3 (10.7%) | |||
T1b | 17 (60.7%) | |||
T1c | 7 (25%) | |||
T2 (N0M0) | 54 (39.4%) | 41 (37.6%) | 13 (46.4%) | |
SABR indication | ||||
Medically inoperable | 103 (94.5%) | 25 (89.2%) | 0.3 | |
Patient refusal | 6 (5.5%) | 3 (10.7%) | ||